Humana
HUM · What the business does, what can go wrong, and how options sellers approach it
What it does
Humana is a US health insurer with a heavy focus on government-sponsored programs. Most of its members are covered through Medicare Advantage, Medicaid, or the military's Tricare program. It also sells standalone Medicare prescription drug plans.
Beyond insurance, Humana runs healthcare services businesses, including primary care clinics, at-home care, and pharmacy services.
How it makes money
Most revenue comes from premiums. Government programs pay Humana a set amount per member, and Humana takes on the risk of paying that member's medical bills. The difference between premiums collected and medical costs paid is the core of its profit. Insurers also earn income on the cash they hold before claims are paid.
The services businesses add fees and revenue from delivering care and filling prescriptions, including for its own members.
Why investors own it
Investors often see Humana as a way to invest in an aging population and the growth of private Medicare plans. Its scale and deep experience in Medicare Advantage can matter in a business where pricing, data, and care management drive results. Its services arms may help it manage costs and keep members engaged. The company has also historically paid a dividend, though dividends can change.
What can go wrong
Humana depends heavily on government payment rules, so changes in rates or policy can hit profits quickly. Medical costs can rise faster than expected, and premiums are usually set well ahead of time. Government reviews of how plans are paid and rated can also affect results. Because its business is concentrated in Medicare Advantage, it has less diversification than some peers.
Regulatory changes, rising use of care, and quality ratings that influence payments are ongoing risks.
What to watch
- Medical cost ratio (also called medical loss ratio)
- Medicare Advantage membership trends
- Annual government rate notices for Medicare Advantage
- Star quality ratings
- Risk adjustment and coding policy changes
- Utilization trends for hospital and outpatient care
- Company guidance updates
Options income angle
Options on HUM are generally liquid, with a wide range of strikes and expirations, though trading is thinner than in the largest mega-cap stocks. Implied volatility tends to rise ahead of earnings, government rate announcements, policy news, and updates on medical costs across the insurance sector.
One caution: the stock can gap sharply on guidance changes or policy headlines, which can turn a short option position into a large loss that premium collected may not offset. Selling premium around known events deserves extra care.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 19, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Humana grew revenue in 2025 but earned about the same profit as the year before, as a smaller individual Medicare Advantage business and large one-time charges offset higher premiums. The filing's biggest open issues are a drop in Medicare Advantage quality ratings and a court fight over how the government audits Medicare billing data. Management is guiding to sharp membership growth in 2026.
How the business did
- Total revenues were $129,664 million, up 10.1%, with premiums revenue of $122,825 million. Higher per-member Medicare premiums, driven by the Inflation Reduction Act, and growth in state-based contracts and stand-alone drug plans (PDP) drove the increase.
- Net income attributable to Humana was $1.2 billion, or $9.84 per diluted common share, against $1.2 billion, or $9.98, in 2024. Items management called out included put/call valuation adjustments of $513 million, value creation initiative charges of $449 million, impairment charges of $253 million and a loss on sale of business of $67 million.
- The benefit ratio (medical and drug costs as a share of premiums) rose to 90.2% from 89.8%. Individual Medicare Advantage membership fell to 5,249,300 from 5,661,800, partly from exiting unprofitable plans and counties. Humana also finished exiting its Employer Group Commercial Medical Products business.
- Insurance segment income from operations was $1,664 million versus $1,289 million. CenterWell, the care delivery segment, was nearly flat at $1,339 million versus $1,329 million, as primary care revenue grew but a Medicare risk model revision (v28) pressured its costs.
- Operating cash flow was $921 million versus $2,966 million, which management attributed to timing items, including larger receivables tied to the Inflation Reduction Act. Cash and cash equivalents rose to $4.2 billion. Dividends were $430 million and share repurchases were $151 million.
Risks specific to this company
- Star Ratings: The number of Medicare Advantage plans rated 4-star or higher declined significantly in 2025. Humana has sued to vacate the 2025 ratings, and if it loses, 2026 quality bonus payments from CMS (the Medicare regulator) will fall.
- Audits of billing data: CMS audits whether diagnoses submitted for Medicare Advantage members justify the payments received (called RADV audits). A court vacated the Final RADV Rule on September 25, 2025, but the government appealed to the Fifth Circuit. CMS has said it will audit all eligible contracts and expedite audits for payment years 2018 through 2024 by early 2026.
- Government dependence: Medicare, military and Medicaid programs were approximately 93% of total premiums and services revenue. About 1.0 million Florida Medicare Advantage members accounted for approximately 14%, under CMS contracts that generally renew annually.
- Drug plan cash strain: Humana finances CMS's share of Part D drug costs until settlement. Its net receivable from CMS for subsidies and brand name prescription drug discounts was $1.5 billion versus $530 million a year earlier.
- Asset values: The home solutions unit carries $4.4 billion of goodwill, and the filing says unfavorable assumptions could significantly hurt its estimated value. Indefinite-lived intangible asset impairments were $128 million in 2025.
- Credit and cash access: Ratings were BBB at S&P and Baa2 at Moody's. The parent company relies on dividends from regulated insurance subsidiaries, with ordinary dividends of approximately $1.1 billion allowed in 2026.
What management is watching
- Management expects 2026 net membership growth of approximately 25% in individual Medicare Advantage, approximately 150,000 members in group Medicare Advantage, approximately 1,000,000 members in stand-alone PDP, and 25,000 to 100,000 members in state-based contracts.
- A multi-year transformation program aims to realign costs, operations and technology, and management expects additional charges over its course.
- On February 13, 2026, Humana completed the acquisition of a primary care business for approximately $941 million.
- The filing points to the benefit ratio and the operating cost ratio (administrative spending as a share of revenue excluding investment income) as its key performance measures.
- Management tracks value-based care, where providers share cost risk. At December 31, 2025, approximately 3,586,100 members, or 68%, of individual Medicare Advantage members were in such arrangements, versus 3,994,300 members, or 71%, a year earlier.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 6, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Humana's revenue grew sharply in the third quarter, but profit from running the business fell as medical costs rose faster than premiums. Net income attributable to Humana was $162 million, or $1.33 per diluted common share, compared with $195 million, or $1.62, a year earlier. A $358 million gain from revaluing options tied to a primary care partnership helped the bottom line.
How the business did
- Revenue and costs: Total revenues were $41,155 million versus $32,649 million, driven by Medicare membership growth and higher per-member payments. The benefit ratio (medical and drug costs as a share of premiums) rose to 93.9% from 91.1%. Income from operations fell to $75 million from $400 million. For the nine months, net income attributable to Humana was $2.0 billion, or $16.84 per diluted share, versus $16.43.
- Why costs rose: The filing points to the Bonus Year 2026 Star Ratings revenue headwind, new Medicare Advantage members who cost more than retained ones, and smaller favorable prior-period claims reserve development ($67 million versus $275 million).
- Segments: The Insurance segment posted a loss from operations of $303 million, versus income of $251 million. CenterWell income from operations fell to $243 million from $305 million, with higher primary care costs concentrated in a group of patients in a single geography. The operating cost ratio (administrative spending efficiency) improved to 11.3% from 12.6%.
- Cash and capital: Operating cash flow for the nine months was $5.4 billion versus $2.6 billion, helped by working capital timing. Cash and cash equivalents were approximately $6.9 billion. The company paid dividends of $320 million and repurchased shares for $103 million. In March 2026 it issued $1.0 billion of 6.625% junior subordinated notes.
- Unusual items: Starting July 1, 2026, the company acts as central processor for the Medicare GLP-1 Bridge. Net receipts from contract deposits were $2.0 billion, and the company says these are not revenue or expense.
What management is watching
- Cash seasonality: Management expects significant operating cash outflows in the remainder of 2026 because of seasonal patterns. Medicare benefit costs also rise through the year, and marketing costs concentrate in the second half.
- Restructuring: Value creation and transformation charges were $25 million for the quarter and $179 million for the nine months. The company expects additional charges over the course of the program.
- Primary care ownership: In October 2026, the company entered a new joint venture with BlackRock-managed funds, majority owned by BlackRock, replacing the prior WCAS arrangements. It has committed capital for existing clinics, new clinics and acquisitions. MaxHealth was acquired in February 2026 for approximately $908 million, net of cash acquired.
- Measures cited: Management points to the benefit ratio and operating cost ratio. Value-based care covered 64% of individual Medicare Advantage members, versus 68% a year earlier. Subsidiaries held statutory capital and surplus of approximately $15.7 billion against minimum requirements of $8.9 billion.
Follow HUM in Kortex
The Kortex app shows HUM's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.